Millennium Management’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-150,000
Closed -$160K – 6108
2026
Q2
$160K Buy
150,000
+15,000
+11% +$43.8K ﹤0.01% 5378
2026
Q1
$506K Buy
+135,000
New +$532K ﹤0.01% 4763
2024
Q3
– Sell
-100,000
Closed -$316K – 6041
2024
Q2
$316K Buy
+100,000
New +$397K ﹤0.01% 4881

Other funds holding ADCT

Millennium Management's ADCT Position: Q3 2026 in Review

Millennium Management sold out of ADC Therapeutics (ADCT) in Q3 2026, closing a stake of 2,899,535 shares — an estimated $3.1M sold.

Millennium Management first reported a position in ADCT in Q2 2020 and held it in 21 quarters. The position peaked at $13.1M in Q4 2022. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • Millennium Management reported no remaining ADC Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Millennium Management sold 2,899,535 ADC Therapeutics shares in Q3 2026, an estimated $3.1M.
  • Millennium Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 21 quarters.
  • Millennium Management's ADC Therapeutics position peaked at $13.1M in Q4 2022.
  • 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.